XML 53 R42.htm IDEA: XBRL DOCUMENT
v3.19.2

Long-Term Investments (Details 2) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018
--- | --- | ---
Non-marketable Cost Method Investments, net abstract |  |
Sub total | $ 1,955,301 | $ 1,985,663
Total | 3,335,463 | 3,488,169
BioFirst Corporation [Member] |  |
Non-marketable Cost Method Investments, net abstract |  |
Total | 1,380,162 | 3,335,463
Rgene Corporation [Member] |  |
Non-marketable Cost Method Investments, net abstract |  |
Total |  |
Braingenesis Biotechnology Co., Ltd. [Member] |  |
Non-marketable Cost Method Investments, net abstract |  |
Sub total | 7,103 | 7,213
Genepharm Biotech Corporation [Member] |  |
Non-marketable Cost Method Investments, net abstract |  |
Sub total | 21,685 | 22,021
BioHopeKing Corporation [Member] |  |
Non-marketable Cost Method Investments, net abstract |  |
Sub total | $ 1,926,513 | $ 1,956,429

X
- References No definition available. + Details
Name: | abvcd_NonmarketableCostMethodInvestmentsNet
Namespace Prefix: | abvcd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | abvcd_NonmarketableCostMethodInvestmentsNetAbstract
Namespace Prefix: | abvcd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_BioFirstCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=abvcd_RgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BraingenesisBiotechnologyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_GenepharmBiotechCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvcd_BioHopeKingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |